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In the United States, lung cancer remains the leading cause of cancer-related death for 
both men and women. The American Cancer Society estimates that in 2014, lung cancer 
represented over 25% of all cancer fatalities.1 
The National Cancer Database (NCDB) is a hospital-based outcomes data resource that is 
estimated to capture 70% of newly diagnosed lung cancers in the United States. The 
NCDB is jointly sponsored by the American College of Surgeons and the American 
Cancer Society and represents the largest clinical oncology databases in the world.2 The 
database has previously been used to study patterns of care and overall survival in 
different non-small cell lung cancer subsets (NSCLC), and the immense size and breadth 
also leaves the NCDB uniquely suited to study less common oncologic scenarios. 
We chose to utilize the NCDB for two studies: First, we studied patterns of care of 
clinical stage IIIA-cN2 NSCLC patients to understand the management of this disease 
and the factors that influence treatment and outcomes. Second, we investigated the 
survival among incompletely resected NSCLC patients and attempted to identify the 
optimal response to positive surgical margins. 
Management of Clinical Stage IIIA Primary Lung Cancers  
The absence or presence of mediastinal lymph node metastases (N2 disease) is important 
to both the prognosis and management of NSCLC.3 The optimal treatment response to the 
presence of N2-positive NSCLC is uncertain as data can be found to support both 
surgical and nonsurgical approaches.4 Accurate clinical staging of the mediastinum is 
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very important, because the N2 designation typically differentiates these patients from 
early stages with better prognostic and entirely different treatment implications.5 
Unfortunately, the accuracy of the clinical staging of the mediastinum can be highly 
variable given that noninvasive staging techniques have false positive rates of 25% to 
40%,6 and invasive mediastinal staging is often done with varying frequency and 
effectiveness.7 Therefore, the completeness of the clinical mediastinal staging evaluation 
should be considered a critical consideration to the management of NSCLC in the United 
States. We chose to study this controversial cohort in the NCDB in order to better 
understand assess how this situation is managed in the United States. 
Impact of Adjuvant treatment for Microscopic Residual disease  
Surgical resection with complete tumor removal (R0) is the standard of care for 
locoregionally confined NSCLC and is associated with the best survival for acceptable 
risk patients.5 However, an estimated 6% of patients are left with microscopic (R1) or 
macroscopic (R2) disease at the surgical margin.8,9 The presence of residual disease at the 
surgical margin is an established marker for compromised survival,10-12 resulting in a 
decrease in 5-year survival of approximately 50%.9 
Recognizing the negative prognostic implications of positive surgical margins, clinicians have 
employed a variety of adjuvant therapy approaches in hopes of extending survival. The fortunate 
the rarity of this scenario, however, has resulted in a lack of data and a paucity of concrete 
recommendations to guide clinicians in this situation. For example the National Comprehensive 
Cancer Network recommends a multitude of options for positive NSCLC surgical margins (re-
resection alone, re-resection with adjuvant chemotherapy, adjuvant radiation therapy alone, or 
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adjuvant radiation therapy with adjuvant chemotherapy therapy).13 These recommendations are 
based on a lower level of evidence (consensus, but not uniform within the committee, category 
2B),13,14 highlighting the lack of suitable primary or secondary evidence in this area. 
Therefore, in our second study, we chose to analyze the longitudinal outcomes associated with 
various adjuvant therapies for incompletely resected NSCLC in the NCDB in order to identify 
the optimal management when faced with this challenging clinical problem.   
METHODS 
National Cancer Database 
The NCDB is a hospital-based data resource founded in 1988 as a joint project of the 
American Cancer Society and Commission on Cancer. The NCDB captures patient, 
tumor, treatment, and longitudinal follow-up data for an estimated 70% of newly 
diagnosed cancer patients cared for by over 1400 hospitals in the United States. The 
NCDB maintains “the data used in the study are derived from a de-identified NCDB file. 
The American College of Surgeons and the Commission on Cancer have not verified and 
are not responsible for the analytic or statistical methodology employed, or the 
conclusions drawn from these data by the investigator.”2 
Study Population 
Management of Clinical Stage IIIA Primary Lung Cancers  
In accordance with our Institutional Review Board-approved clinical research protocol, 
the NCDB was queried for histologically confirmed non-small cell lung cancer (NSCLC) 
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patients age 19 years or greater, diagnosed and clinically staged between 1998 and 2011, 
representing the patient's first primary cancer (n = 760,484). Patients were further 
specified as being clinical stage III (5th and 6th editions of the American Joint 
Commission on Cancer staging manual) and T1-3, N2, and M0. Patients with missing 
data for treatment were excluded. The final patient population was 83,913. 
Impact of Adjuvant treatment for Microscopic Residual disease  
In accordance with our Institutional Review Board-approved clinical research protocol, 
treatment naïve (no preoperative chemotherapy or radiation) patients 19 years or older 
diagnosed with non-small cell lung cancer (NSCLC) as their first and only primary 
invasive cancer, between 2003 and 2006 were evaluated. Inclusion criteria consisted of 
NSCLC histology codes,15 undergoing surgery (bronchial sleeve resection, wedge 
resection, segmental resection, lobectomy or bilobectomy, extended lobe or bilobectomy, 
pneumonectomy or extended pneumonectomy), and pathological stage I – III NSCLC. 
Patients that received neoadjuvant chemotherapy or neoadjuvant radiation, hormone 
therapy, immunotherapy, or palliative care were excluded. Patients that died within 30 
days of surgery were excluded because they would likely not have survived long enough 
to receive adjuvant therapy. Patients with missing data for treatment were excluded. 
The final analytic cohort contained 54,512 patients. Of these, 51,410 patients were coded 
by the NCDB as “no residual tumor” (R0) at the surgical margins.16 The NCDB considers 
“no residual tumor” to include cases where all surgical margins were grossly and 
microscopically negative after resection of the primary tumor. 3,102 patients in the 
population were classified as having an incomplete resection, of which 1,688 had 
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microscopic residual tumor (R1). Microscopic residual tumor is defined in the NCDB as 
residual disease that cannot be seen by the naked eye. 181 cases were coded as 
macroscopically residual tumor (R2), defined as gross tumor of the primary site that is 
visible to the naked eye. Additionally 1,233 of the 3,102 cases of incomplete resection 
were coded as “residual tumor, NOS” indicating that residual disease at the primary site 
was present following surgery, but further information is not available. 
Study Variables 
Study variables were analyzed as defined by the Participant User Data File dictionary 
(available at http://ncdbpufbeta.facs.org/?q=node/259). 
The measures for education level, household income, and urban/rural status were 
determined for each patient’s area of residence by matching the zip code of the patient at 
the time of diagnosis to 2000 US Census.17 The NCDB represents comorbidity as a 
modified Charlson-Deyo score reflecting 15 comorbid conditions and classifies patients 
into three categories: 0, 1, and 2+.18 
It was determined prior to analysis that “adjuvant” therapy would only include treatment 
that was given after surgery, but within 180 days of diagnosis (as treatment beyond this 
time point could reflect disease progression).  
The adjuvant radiation therapy group was determined by using the NCDB’s “Radiation 
Surgery Sequence” data item that specifies the temporal relationship of the radiation 
therapy to the primary surgical procedure. Cases in which radiation was coded as being 
administered to a site other than the chest, lungs, chest wall, or chest wall lymph nodes, 
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cases in which the recorded most clinically significant dose during the first course of 
treatment was less than or equal to 1000 cGy, or cases in which radiation therapy was not 
started at or before 180 days from diagnosis were considered to have no radiation. 
The adjuvant chemotherapy group was determined by using the “Systemic Surgery 
Sequence” data item that specifies the temporal relationship of the chemotherapy to the 
primary surgical procedure for cases diagnosed in 2006. This code was not put in place 
until 2006, so cases diagnosed between 2003 and 2005 were determined by comparing 
the number of days elapsed from diagnosis to the date of definitive surgery, and the 
number of days elapsed from diagnosis to the start of chemotherapy.  
Statistics 
Management of Clinical Stage IIIA Primary Lung Cancers  
The patients were divided into 3 separate cohorts (a priori) to reflect important 
differences in the availability specific database variables (cohort 1 = 1998 to 2002, cohort 
2 = 2003 to 2006, and cohort 3 = 2007 to 2011). More specifically 5-year survival 
information is only available from 1998 to 2006 (cohorts 1 and 2) and the modified 
Charlson-Deyo comorbidity index from 2003 to 2011 (cohorts 2 and 3). 
Logistic regressions were performed in cohorts 2 and 3 to understand the factors 
associated with various treatment strategies (surgery, nonsurgical, and no treatment). 
Patients who were untreated were compared with patients who received nonsurgical 
treatment (as they were felt to represent more similar patient populations and likely 
different from the surgical population). In addition, surgically treated patients were 
! 7 
compared with nonsurgically treated patients. The variables considered included the 
following: race; sex; age; CD score (modified Charlson-Deyo score that included only 3 
options, 0, 1. or ≥ 2); histology; year of diagnosis; clinical T stage; Hispanic origin; 
insurance status; laterality; facility type; facility location; sequence number (refers to 
patients having multiple cancers; while only patients in whom NSCLC was first cancer 
were entered into study); crowfly distance of treating facility to patients home; education 
(% without high school diploma); urban rural status; and income. These variables were 
first considered in a univariate analysis with those with a p value less than 0.05 being 
carried forward to the multivariable analysis. Sex of the patient, while not statistically 
significant, was forced in as it was felt to represent a clinically relevant consideration. 
Survival was calculated for each treatment approach first using the Kaplan-Meier 
method. The survival data are only available for cohorts 1 and 2. We selected cohort 2 to 
study survival in more detail because it also contained comorbidity data. 
A Cox survival analysis was performed using cohort 2. A univariate analysis for 
correlation with survival was performed using the following variables: treatment 
approach (surgery alone, surgery with chemotherapy, radiation, or both nonsurgical 
treatment, or no treatment), race, sex, age, CD score (modified Charlson-Deyo score), 
histology, year of diagnosis, clinical T stage, Hispanic origin, insurance status, laterality, 
facility type, facility location, sequence number (refers to patients having multiple 
cancers, while only patients in whom NSCLC was first cancer were entered into study), 
crow fly distance of treating facility to patients home, education (% without high school 
diploma), urban rural status, income. 
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Variables that demonstrated a significant association with 5-year survival (p < 0.05) were 
evaluated in the multivariable Cox model, and the final model derived by stepwise 
backward elimination. Missing data were managed by classifying missing information as 
“unknown” in order to assess potential associations with missing information and 
outcome. 
The mortality associated with laterality in patients undergoing pneumonectomy after 
receiving induction chemotherapy ± radiation was a predetermined query based on 
published literature suggesting a difference. Thirty-day mortalities among right and left 
pneumonectomies were compared using the Fisher exact test. All statistical analyses were 
performed using SAS version 9.3 (Cary, NC). 
Impact of Adjuvant treatment for Microscopic Residual disease  
Estimates of overall survival, stratified by pathological stage and margin status, were 
calculated using the Kaplan-Meier method with log-rank test. Survival in the NCDB is 
calculated from the time of diagnosis. 
Multivariable logistic-regression models were developed to identify predictors of margin 
status (positive or negative). First, bivariate analysis using the chi-squared test for 
categorical covariates and one-way analysis of variance (ANOVA) for continuous 
covariates was used to examine differences by surgical margins status. The variables 
considered included: year of diagnosis, pathologic T stage, pathologic N stage, Charlson-
Deyo Score, age, gender, race, Hispanic origin, insurance status, household income, 
education level, urban/rural status, “great circle distance” (or the distance between the 
patient's residence and the hospital that reported the case), facility location, facility type, 
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laterality, histology, primary site, grade, and surgical procedure. Those variables with a p 
<0.2, were entered into the logistic regression model. Age, gender, year of diagnosis, 
Charlson-Deyo Score, and grade, while not statistically significant, were forced in as it 
was felt to represent a clinically relevant consideration. Logistic regression model data 
are reported using odds-ratios, 95% confidence intervals, and p-values. 
Survival analyses were performed on the cohort of patients with microscopically positive 
margin (R1) population, as this was felt to be the more homogeneous, and potentially 
salvageable scenario. Overall survival was also estimated using the Kaplan-Meier method 
and was stratified by pathological stage and treatment type cohort (No Adjuvant Therapy, 
Chemotherapy Alone, Radiation Alone, and Chemotherapy + Radiation).   
In the microscopically positive (R1) population, stage-stratified adjusted survival 
analyses were performed to assess the impact of treatment type on overall survival. Cox 
proportional hazard models were developed in several steps. First, the association 
between the adjuvant therapy type (No Adjuvant Therapy, Chemotherapy Alone, 
Radiation Alone, and Chemotherapy + Radiation) and 19 potential confounder variables 
(year of diagnosis, pathologic T stage, Charlson-Deyo Score, age, gender, race, Hispanic 
origin, insurance status, household income, education level, urban/rural status, “great 
circle distance” (or the distance in miles between the patient’s residence and reporting 
hospital), facility location, facility type, laterality, histology, primary site, grade, and 
surgical procedure) was examined by bivariate analysis using the chi-square test for 
categorical covariates or ANOVA for continuous covariates. Variables were inspected for 
co-linearity and to confirm that none of the variables violated the proportional hazards 
assumption. Those variables that fit the above criteria and with a p value of less than 0.2 
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or those chosen based on clinical relevance were entered into the Cox proportional 
hazards model. Both backwards and stepwise elimination were used in creation of the 
final model with a significance value set at p<0.05 to stay in the model. For clinical 
relevance, age, year of diagnosis, pathologic T stage, gender, histology, Charlson-Deyo 
Score, and surgical procedure were forced into the model when necessary. All data 
elements, except for age, were treated as nominal covariates. The specific cut points were 
chosen a priori and were based on the distribution of values, not patients. The primary 
end point was date of death, measured from the date of first diagnosis.   
The final Cox proportional hazard model for each stage was used to estimate the relative 
impacts of adjuvant therapy strategies on 5-year overall survival (OS). Hazard ratios 
(HRs) and corresponding 95% confidence intervals (CIs) were estimated in models 
adjusted for covariates of interest. All analysis was performed using SAS version 9.3 
(SAS Institute, Cary, North Carolina). A p-value of <0.05 was set as the threshold for 
significance.  
RESULTS 
Management of Clinical Stage IIIA Primary Lung Cancers  
Study Population 
83,913 clinical stage IIIA NSCLC patients with clinical N2 nodal metastases (cStage III-
cN2) were identified in the NCDB from 1998 to 2011, representing 11% of all of the 
NSCLC cases in the NCDB and 36% of the clinical stage III NSCLC cases. The 
population was separated into 3 time cohorts (1998 to 2002, 2003 to 2006, 2007 to 2011) 
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in order to observe temporal trends and to cluster patients with similar complete data, as 
outlined in the Methods section. The patient and tumor characteristics were very similar 
across the 3 cohorts (Table 1). 















! ! ! !   Mean 67 67 68 0.287 
   Median 69 68 68 
!   Interquartile range 15 16 16 
!Charlson Deyo score (%) 
!
<0.0001 
0 NA 65 59 
!1 NA 25 28 




 Male 59 57 55 




 White 86 86 85 
! Black 11 11 12 
! Other 2 2 2 
! Unknown 1 1 1 
!Insurance status (%) 
! !
<0.0001 
 No insurance 3 3 3 
! Private insurance, managed care 32 30 28 
! Medicaid 4 5 6 
! Medicare 56 58 59 
! Other Government insurance 1 2 2 



















Facility type (%) 
! !
<0.0001 
 Community Cancer Program 
(CCP) 12 13 13 
! Academic/research 26 27 27 
! Comprehensive CCP 59 58 59 




 Left 35 34 35 
! Right 58 60 59 
! Midline or bilateral 0 0 0 




 Adenocarcinoma 34 28 36 
! Bronchioalveolar 1 1 2 
! Squamous cell carcinoma 43 35 40 
! Other 22 36 22 
!Clinical T stage (%) 
! !
<0.0001 
1 18 20 22 
!2 55 55 52 




1 3 2 3 
!2 17 16 19 
!3 37 34 34 
!4 5 3 2 







Table 1. Demographics, Tumor Attributes, and Management in 3 
Time-Based Cohorts (cont.) 
Variable 
Cohort 1 Cohort 2 Cohort 3 p Value 
1998-2002  2003-2006 
2007-
2009 
Tumor size (%) 
! !
<0.0001 
 <10 mm 1 1 1 
! 10-19 mm 4 6 9 
! 20-29 mm 11 13 15 
! 30-39 mm 14 15 16 
! 40-49 mm 13 13 14 
! 50-59 mm 11 11 11 
! 60+ mm 20 21 23 
! Unknown 26 20 11 
!Primary site (%) 
! !
<0.0001 
 Main bronchus 7 6 5 
! Upper lobe 57 58 59 
! Middle lobe 5 4 4 
! Lower lobe 23 24 26 
! Overlapping 
lesion 2 2 1 
! Lung, NOS 6 6 5 
! 
Accuracy of Nodal Staging of Clinical Stage III-cN2 Patients in the NCDB 
The NCDB does not include data on the mechanism by which the clinical stage was 
determined (i.e., positron emission tomography [PET] scan, mediastinoscopy). We use 
two strategies were to extrapolate the completeness and accuracy of the clinical 
mediastinal lymph node evaluation. The first strategy took advantage of the fact that the 
NCDB captures the number of lymph nodes that are examined or aspirated from a 
patient. Only nonsurgical patients were studied to avoid confusion between lymph nodes 
evaluated as a part of the clinical staging process and lymph nodes that were removed at 
the time of definitive surgical resection. Among cStage IIIA-cN2 patients treated without 
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surgery, only 22.7% (13,178 of 58,016) had 1 or more lymph node examined 
pathologically or aspirated. Of note, there was increased use of aspiration (1% in cohort 1 
and 8% in cohort 3), likely reflecting the more common use of endobronchial ultrasound 
in that time span. In patients who are not treated at all, the rate of lymph node evaluation 
has been relatively stable at over the 3 time cohorts around 17%. It is important to note 
that the specific nodal region (N1, N2, or N3) is not captured by NCDB. 
The second strategy used to assess the clinical staging evaluation was compare the 
clinical nodal stage (cN2) with the pathologic stage (resulting from a pathologist's review 
of a therapeutic lung surgery tissue) and assess for “overstaging,” or the failure to 
confirm clinical N2 status by examining the definitive surgical specimens. In order to 
avoid confusion from potential downstaging as a result of neoadjuvant treatment (i.e., 
chemotherapy, radiation, or both), this analysis was limited to treatment-naïve (no 
neoadjuvant) surgical patients. Overall, 56% of treatment-naïve cStage IIIA-cN2 patients 
were confirmed to have N2 metastases in the surgical specimen cN2→pN2, which 
increased over the study (48% in cohort 1 and 59% in cohort 3 as shown in Table 2. On 
the other hand, 33% of treatment-naïve patients appeared to have been overstaged by the 
clinical exam (cN2→pN0 or pN1). An additional 10% of patients were coded as “NX,” 





Table 2. Distribution of Pathologic N Stage Among cStage III-cN2 Patients 
Undergoing Surgery as First Line of Treatment (no Neoadjuvant Therapy) 














pN0 (%) 24 20 22 22 
pN1 (%) 10 9 11 11 
pN2 (%) 48 57 59 56 
pN3 (%) 1 1 0 0 
pNX (%) 17 13 8 11 
 
Management of cStage IIIA-cN2 Patients 
The distribution of management approaches of cStage IIIA-cN2 patients is shown in 
Table 3; 17% of cStage IIIA-cN2 patients are recorded as being untreated. The majority 
of patients (69%) were treated nonsurgically, including chemotherapy alone (11% of all 
cStage IIIA-cN2 patients), radiation alone (14%), or chemoradiation (44%). 
Table 3. Management of Clinical Stage III-cN2 NSCLC Over 3 Time Periods 
! ! ! ! !








Surgical treatment (%)a 12 13 17 14 
Nonsurgical treatment (%)b 72 70 66 69 
No treatment (%) 16 17 17 17 
! ! ! ! !a Includes patients who only underwent surgery as well as those treated with additional 
therapies (chemotherapy or radiation), before or after surgery (neoadjuvant or 
adjuvant). 
b Includes chemotherapy and radiation, alone or in combination. 
! 
Surgery was used in 14% of patients, increasing slightly over the study period from 12% 
in cohort 1 to 17% in cohort 3. Surgery was performed as the only therapy in 3% of 
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patients, and in combination with chemotherapy, radiation, or both in 11% (given before 
or after surgery). The specific surgical procedure was most commonly a lobectomy 
(73%) followed by pneumonectomy (16%) (Table 4). Over time the use of 
pneumonectomy appears to have declined (22%, 16%, and 12% in cohorts 1, 2, and 3, 
respectively). Negative margins were recorded in 86% of patients, a positive margin 
indicated in 10%, and margins were not evaluable or unknown in 4%. Overall the 30-day 
mortality was 3.5% and varied by surgical procedure as follows: lobectomy (2.8%), 
pneumonectomy (7.8%), wedge (3%), and segmentectomy (5%). Pneumonectomy 
mortality among patients receiving induction chemotherapy or chemoradiation was 
higher for right pneumonectomy (12.3%, 51 of 363) than for left (4.7%, 18 of 369, p = 
0.0001). 
Table 4. Extent of Surgical Resection of Clinical Stage III-cN2 Non-Small Cell Lung 
Cancer Over 3 Time Periods 
! ! ! ! !








Wedge resection (%) 9 9 10 9 
Segmental (%) 2 2 2 2 
Lobectomy/bilobectomy (%)a 67 73 76 73 
Pneumonectomy (%)b 22 16 12 16 
! ! ! ! !a Also includes sleeve resections, or extended lobectomy (chest wall, pericardium, 
diaphragm). 
b Also includes extended pneumonectomy (pleura or diaphragm) 
! 
Determinates of Treatment 
In order to better understand the factors associated with treatment approaches, a logistic 
regression analysis was performed. Among treated patients, the use of surgery was 
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significantly increased in the most recent time cohort and those treated at academic 
centers. On the other hand, African Americans, older patients, right-sided tumors, 
squamous cell carcinomas, and tumors with advancing T status were less likely to 
undergo surgery (Figure 1). Surprisingly, increasing number of comorbidities (CD score) 
was not associated with less frequent use of surgery. 
Figure 1. Forest plot of logistic regression comparing clinical stage IIIA-cN2 patients 
who were treated surgically to those treated with nonsurgical approach (chemotherapy, 
radiation, or chemotherapy + radiation). (CI = confidence interval.) 
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The NCDB also captures the reason why surgery was not performed. The most common 
reason listed for no surgery among patients treated with chemotherapy, radiation, or both 
was “Surgery was not part of the planned first course of treatment” (85%). In 3% of 
nonsurgically treated patients, surgery was actually recommended but the patient either 
refused treatment (510 patients) or surgery was not performed for other unknown reasons 
(1,063 patients); 45 patients died prior to planned or recommended surgery. 
In order to better understand the untreated population, a logistic regression was 
performed comparing untreated patients to those who received nonsurgical treatment 
(Figure 2). Several factors were associated with receiving no treatment, including 
advancing age, nonwhite race, insurance status (“no treatment” was more likely with 
Medicaid or no insurance), increasing comorbidities, right sided tumors, treatment at 
community cancer centers, advanced T status, and increasing distance between the 









Figure 2. Forest plot of logistic regression comparing clinical stage IIIA-cN2 patients 
who were untreated to those who were treated with nonsurgical approach (chemotherapy, 
radiation, or chemotherapy + radiation). (CI = confidence interval.) 
 
 
Survival of cStage IIIA-cN2 in the NCDB 
A limited temporal analysis of survival was performed comparing cohorts 1 and 2 
(survival information unavailable for cohort 3). The entire cStage IIIA-cN2 population 
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fared better in cohort 2 (14% 5-year survival) compared with cohort 1 (10%). The 
survival increased for each of the general treatment strategies from cohort 1 to cohort 2 
(surgery 28% to 36%, nonsurgical treatment 9% to 11%, no treatment 3% to 5%). 
Because only cohort 2 has both survival information and comorbidity data, a more 
detailed analysis was performed on these patients stratifying survival according to 
specific treatment approaches. The 5-year survival by Kaplan-Meier survival curves 
according to treatment is as follows: untreated (4.7%), nonsurgical treatment (11.4%), 
surgery alone (30%), and surgery with additional chemotherapy, radiation, or both (38%) 
(Figure 3). 
Figure 3. Kaplan-Meier survival curves of clinical stage IIIA-N2 patients in cohort 2 




To further understand factors associated with survival in the cStage III-cN2 population, a 
Cox multivariable analysis was also performed on cohort 2 (Figure 4). Several variables 
appeared to correlate with survival, most notably including the treatment approach, which 
mirrored findings above. Other factors associated with an improved survival included the 
following: female sex; nonwhite race; private insurance; the absence of comorbidities; 
treatment at an academic medical center; lower clinical T stage; and left-sided tumors. 
Figure 4. Forest plot of Cox survival analysis of clinical stage IIIA-cN2 patients in the 
National Cancer Database. 
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Impact of Adjuvant treatment for Microscopic Residual disease  
Prevalence and Impact of Incomplete Resections   
A total of 54,512 patients who underwent resection of a treatment-naïve NSCLC between 
2003 and 2006 were identified. Some residual disease was identified in 3,102 (5.7%) of 
surgical procedures, including 1,688 (3.1%) with microscopically positive (R1) margins 
and 181 (0.33%) with macroscopically positive (R2) margins.  An additional 1,233 
(2.3%) were coded as “residual disease not otherwise specified (NOS).”  
Overall 5-year survival was determined for each of the pathologic stage groups (I,II,III) 
according to margin status (Table 5).  The presence of a positive margin was associated 
with a decreased 5-year survival for each pathologic stage.  
Table 5.  Stage – specific unadjusted 5 Year overall survival by surgical margin 
status 
 











(51,410) (1,688) (181) (1,233) 
I 62% 37% 22% 45% 
II 41% 29% 34% 27% 
III 33% 19% 12% 13% 
NOS, Not Otherwise Specified. 
! ! 
Predictors of incomplete resection 
In order to better understand the factors influencing margin status, a logistic regression 
was performed comparing patients with negative (R0) and positive margins (R1, R2, or 
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residual tumor, NOS). Advancing pathologic “T” and “N” stage were associated with 
increased likelihood of positive margins (“T” stage 2 versus 1 OR 2.448, 95% CI [2.209 
to 2.713] p<0.0001 and “N” stage 2 versus 1 OR 2.334, 95% CI [2.122 to 2.568] 
p<0.0001), as was the use of wedge resection compared to anatomic resections (OR 
2.365, 95% CI [2.127 to 2.63] p<0.0001). On the other hand, Academic/Research 
hospitals were associated with a lower incidence of positive margins than Community 
Cancer hospitals (OR 0.782, 95% CI [0.681 to 0.899] p=0.0005). 
Stage-Specific Survival in R1 patients According to Adjuvant Treatment Strategy 
Conceptually, microscopic residual disease (R1) is thought represent a salvageable 
scenario in which additional therapy could contain what was presumed to be 
locoregionally confined NSCLC. Therefore the subsequent multi-variable adjusted 
analyses were focused on R1 patients and excluded macroscopically positive margins or 
patients with “residual disease, not otherwise specified”.  In addition, because several 
stage-specific considerations exist for adjuvant therapy among completely resected 
NSCLC, the R1 patients were analyzed separately by stage (I, II, and III).   
A total of 581 stage pI NSCLC patients with an R1 resection were evaluated. The 
unadjusted 5-year survival with no adjuvant therapy was 35%. The addition of either 
chemotherapy alone (5-year survival = 55%;p=0.0009), or chemotherapy + radiation (5 
year survival = 44%;p=0.05) were associated with a superior survival.  The addition of 
radiation alone was not (5-year survival = 26%;p=0.0399) (Figure 5A).  
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Figure 5. Kaplan Meier survival analysis demonstrating 5 year overall survival of 
patients with a microscopically positive margin according to adjuvant strategy for A) 
Pathologic stage I, B) Pathologic stage II, and C) Pathologic stage III NSCLC. 
 
 
In attempt to adjust for heterogeneity in the stage pI cohort, a Cox proportional hazards 
model was created (variables and strategy given in METHODS section) to evaluate 
predictors of survival. Advancing age, increasing comorbidities, pT2 status (compared to 
T1), and the use of sublobar resection were associated with a significant decrease in 
survival (Figure 6). Compared to “no adjuvant therapy,” postoperative chemotherapy 
alone was the only adjuvant strategy to be associated with a significantly superior 
outcome (HR 0.644, 95% CI [0.454 to 0.915] p=0.014, while chemotherapy + radiation 
(HR 0.732, 95% CI [0.516 to 1.039] p=0.081) trended towards a better outcome.  
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Interestingly, radiation alone was not associated with an improvement in survival over 
“no adjuvant therapy” in this multivariable model (HR 1.125, 95% CI [0.878 to 1.442] 
p=0.35 (Figure 6). 
Figure 6. Forest plot demonstrating a Cox proportional hazards model for stage pI 




A total of 517 stage pII patients with R1 resection were identified. The unadjusted 5-year 
survival with no adjuvant therapy was 21%. The addition of chemotherapy alone (5-year 
survival = 37%;p=0.0023), or chemotherapy + radiation (5-year survival = 
33%;p=0.0013), or radiation alone (5-year survival 32%;p=0.0441) were all associated 
with significantly superior survival (Figure 5B). 
In an adjusted analysis of R1-resected stage pII patients, advancing age was a predictor of 
poorer survival, while the association between comorbidities, advancing “T” status (pT2 
or pT3 status compared to T1), and extent of resection performed (i.e. lobectomy vs. 
wedge) and survival was less clear (Figure 7). Chemotherapy alone (HR 0.701, 95% CI 
[0.516 to 0.954] p=0.024), chemotherapy + radiation (HR 0.711, 95% CI [0.54 to 0.937] 
p=0.016), and radiation alone (HR 0.672, 95% CI [0.508 to 0.89] p=0.0055) were all 










Figure 7. Forest plot demonstrating a Cox proportional hazards model for stage pII 
patients. *1 case with unknown pathologic T stage was excluded from the table. 
 
 
A total of 590 stage pIII patients with R1 resection were evaluated. The unadjusted 5-
year survival with no adjuvant therapy was 12%. The addition of chemotherapy alone (5-
year survival = 18%;p=0.0187), or chemotherapy + radiation (5-year survival = 
30%;p<0.0001), were associated with a superior survival.  The addition of radiation alone 
was not (5-year survival 9%;p=0.9441) (Figure 5C).   
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In an adjusted analysis of R1-resected stage pIII patients, advancing age and the use of 
sublobar resection were again associated with a significant decrease in survival (Figure 
8). Compared to “no adjuvant therapy,” postoperative chemotherapy + radiation was the 
only adjuvant strategy to be associated with a significantly superior outcome (HR 0.583, 
95% CI [0.459 to 0.742] p<0.0001), while chemotherapy alone (HR 0.797, 95% CI 
[0.614 to 1.035] p=0.089) trended towards a better outcome. Radiation alone was not 













Figure 8.  Forest plot demonstrating a Cox proportional hazards model for stage pIII 







With a population of over 80,000 in the cStageIIIA-cN2 NSCLC study and a population 
of over 3000 patients in the positive margins study, the NCDB demonstrates its 
invaluable use as a resource to investigate these subsets and others like them.  
Management of Clinical Stage IIIA Primary Lung Cancers  
As with any investigation concerning a clinically staged population, a key issue becomes 
the accuracy of the clinical stage IIIA-cN2 designation. Somewhat surprisingly, the 
clinical staging evaluation of nonsurgical patients did not involve the examination of 
lymph node tissue by a pathologist in the majority of patients (77%). This implies that 
only noninvasive staging was used to establish N2 status in the majority of nonsurgically 
managed patients. This is concerning because noninvasive staging modalities are 
notorious for overestimating mediastinal lymph node metastases. For example, PET and 
PET-computed tomographic (CT) scans have a 25% false positive rate in the 
mediastinum, and CT scan has over a 40% false positive rate for N2 disease.6 Therefore, 
it is possible that a significant portion of the clinical N2 patients did not in fact have N2 
disease (potentially rendering them as stage I or stage II). The fact that the treatment-
naïve surgical patients were only confirmed as having N2 disease 56% of the time further 
supports this assertion that NCDB patients were prone to overstaging by the clinical 
staging evaluation. While the role of surgery in patients with stage IIIA NSCLC may be 
less clear, surgery has a much more supported role in earlier stage cancer.5 As a result, 
the overstaging of patients may in fact be causing patients to be directed toward less 
effective treatment approaches. Therefore, irrespective of the preferred stage IIIA 
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treatment strategy, in order to optimize care, all patients should be staged with the same 
degree of diligence. 
The management of cStage IIIA-cN2 within the NCDB reflects a trend away from 
surgery among case series, published trials, and national treatment guidelines.4,19 Several 
factors associated with the use of surgery illustrate clear tendencies by patients, providers 
and insurers. Perhaps more concerning are the predictors of “no treatment,” as they could 
potentially reflect important health care disparities. The current study identified race, 
insurance status, the type of facility, and distance between the facility and the patient all 
being associated with a likelihood of not being treated at all. Because no treatment is 
indisputably less effective than treatment, this could translate into worse outcomes in the 
populations affected by these variables. 
Among patients who did undergo surgery, the surgical outcomes in the NCDB compare 
well to the published series. More specifically, the 30-day mortality for lobectomy (2.8%) 
is well within the published range for primary lung cancer surgery7,20 but remains a bit 
higher than that of Society of Thoracic Surgeons (1.8%).21 Of interest, a right-sided 
pneumonectomy after induction chemotherapy, with or without radiation, was associated 
with a higher 30-day mortality than a left-sided (12% vs 5%). The importance of 
laterality for postinduction pneumonectomy has been the subject of ongoing debate, with 
some studies finding a higher mortality with right-sided pneumonectomy22 while others 
have challenged this concept.21,23  
The 5-year survival of the entire cStageIIIA-cN2 population in the NCDB (14%) is on 
par with that of the International Association for the Study of Lung Cancer's staging 
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project (17%).24 The outcomes appear to be best for patients treated with surgery, 
particularly those who were treated with a multimodality approach (including 
chemotherapy, radiation, or both). This almost certainly implies patient factors are at play 
that go beyond the degree to which the NCDB captures. As such, we would not assume 
that this data indicates a superiority of surgery-based treatment approaches. That being 
said, the 5-year survival of surgery-treated patients compares well with clinical trials that 
have studied curative-intent treatment of NSCLC and paints an encouraging picture for 
surgically managed stage IIIA NSCLC in the United States.4 
There are several limitations to this study. The first being the possibility that important 
elements of the patient's care took place at hospitals that are not accredited by the 
Commission on Cancer (CoC), and therefore are not captured by the NCDB. It is the 
responsibility of the submitting CoC hospital to research all aspects of care, including 
elements that occurred at non-CoC hospitals, but this does represent a vulnerability of the 
NCDB for incomplete data. In addition, the treatment within this stage cohort likely 
reflects aspects of the patients and tumors that are beyond the detail captured by the 
database, and therefore treatment-associated outcomes may not be comparable. 
The NCDB represents an invaluable resource for the study of clinical stage III-cN2 
NSCLC. The extent to which the mediastinum has been accurately staged is unclear as 
invasive mediastinal staging appears to have been used sparingly in the nonsurgically 
managed patients, and just over half of the treatment-naïve surgical patients were 
confirmed to have N2 disease. Surgery is used less frequently in clinical stage IIIA-cN2 
disease in the NCDB, but is associated with encouraging outcomes. Further study is 
warranted to clarify the degree to which overstaging is directing patients away from 
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surgery in the United States. 
Impact of Adjuvant treatment for Microscopic Residual disease  
The 3,102 cases of positive margins, to the best of our knowledge, represent the largest cohort of 
incompletely resected NSCLC patients reported in the literature. The incidence of incompletely 
resected NSCLC in the NCDB (5.7%) is well within the range of previous reports (2 - 17%).7-
10,12,25 Furthermore, the positive margin patients in the NCDB experienced a stage-specific 
compromise in survival (relative to completely resected patients), that is similar to other 
longitudinal NSCLC studies.9,11 
Several factors identified to predict positive margins in the NCDB (advancing pathologic T and 
N stages, and use of sublobar resection) echo the findings of other reports.9,26 We did note that 
positive margins were less frequent at academic centers.  This would be consistent with surgical 
studies that have found academic centers to be associated with improvements in surgical quality 
for lung cancer.20 
Adjuvant therapy appears to rescue a fraction of R1 patients from the compromised 
survival associated with residual disease. A number of stage-specific nuances to the 
efficacy of adjuvant therapy for incompletely resected NSCLC were identified.  For 
pathologic stage I NSCLC with R1 resection, chemotherapy appeared to benefit patients 
while radiation alone did not. This is a bit counterintuitive, as pathologic stage I tumors 
are presumed to be confined to the lung parenchyma, and a positive margin would 
represent a risk for local failure, which would theoretically be modifiable by additional 
local therapy (which radiation represents). This finding contradicts several smaller 
studies that have suggested a role of adjuvant radiation for positive margins.25,27,28 The 
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American College of Chest Physicians currently recommends radiation alone in the 
setting of a positive margin for stage I NSCLC.5 On the other hand, the current study is 
not alone in failing to identify a survival advantage with adjuvant radiation.10,12,25,29  
Alternatively, the lack of significant survival advantage with radiation alone may reflect 
an artifact or limitation of the dataset in the NCDB.  The number of patients treated with 
radiation alone is not large (n = 114) and it is possible that the subgroup survival was 
influenced by factors not captured by the NCDB data fields (e.g. lung function).  It is also 
possible that the patient survival is dominated by other cancer-specific risk factors.  For 
example, subgroup analysis of an adjuvant NSCLC chemotherapy trial, CALGB 9633 
suggested that tumors greater than 4cm benefit from adjuvant chemotherapy.30  34% of 
the R1 resections for stage pI NSCLC that were treated with postoperative radiation 
alone, involved tumors that were over 4cm (and potentially could have benefitted from 
chemotherapy based on size alone).   
In patients with stage II disease, all three forms of adjuvant therapy appeared to be 
similarly superior to surgery alone.  Unlike stage I patients, postoperative radiation alone 
was beneficial for incompletely resected stage II. Of the 108 stage II patients treated with 
radiation alone, 58 were “N0”, potentially representing a subgroup that was containable 
with local therapy. However, the discrepant outcome with radiation alone in stage I and II 
in this regard is unclear. 
For stage III patients with a microscopically positive margin, the administration of chemotherapy 
+ radiation was associated with the best outcomes.  Interestingly, the outcome of R1 patients 
treated with chemotherapy and radiation (30%) is actually quite similar to completely resected 
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(R0) pathologic stage III patients (5-year survival of 33% in Table 5).  In some regards, the best 
outcome being seen in R1- resected stage pIII patients treated with adjuvant chemotherapy and 
radiation is not surprising, as trimodality therapy has emerged as the optimal approach in 
completely resected stage pIII NSCLC.31,32 
The principle limitation of the study is the assumption that patient differences in each 
treatment cohort were adjustable using the NCDB data fields.  More specifically, there 
are likely patient and tumor attributes that influenced the use of post-operative therapy 
that are not captured by the NCDB (e.g. pulmonary function).  These concerns grow as 
the stage increases, because the evolving standard of care for R0 patients would have 
been for adjuvant chemotherapy for stage II and chemoradiation for stage III.31,32 
Therefore many of the stage II and III treatment cohorts could be considered deviations 
from the standard of care.  These deviations may have been justified but could reflect 
patient characteristics not captured by NCDB that also influenced survival.  It is worth 
noting that although adjuvant chemotherapy has demonstrated an absolute increase 5-year 
survival benefit of 5% for NSCLC, many of the chemotherapy containing adjuvant 
cohorts experienced two to three times this benefit.  Therefore the effect of adjuvant 
chemotherapy in the R1 patient cohorts is not entirely explained by the generic benefit of 
adjuvant chemotherapy for surgically managed NSCLC.   
It is also important to note that the NCDB does not capture patients in our population 
who underwent re-resection after their initial R1 resection, which is currently 
recommended by the National Comprehensive Cancer Network for stage I or stage II 
NSCLC.13 Additionally, the NCDB does not capture causes of death or sites of 
recurrence, fields that would have been helpful to evaluate efficacy of adjuvant treatment.  
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Positive surgical margin therefore, portends a substantial drop in stage-specific survival in 
NSCLC. There does appear to be an advantage to adjuvant therapy, with the most consistent 
outcomes across all pathologic stages being associated with chemotherapy + radiation.  Further 
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